The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer
N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway
The pioneering monoclonal antibody is for Essential Thrombocythemia (ET) and Polycythemia Vera (PV), rare chronic blood cancers with limited treatment options
LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates
The partnership will launch a Phase 1b cohort within Boehringer’s ongoing Beamion-BCGC1 trial
Kelun-Biotech and Crescent Biopharma forged a collaboration covering SKB105/CR-003 and SKB118, a PD-1 x VEGF bispecific antibody also known as CR-001
GV20 received an upfront payment and is eligible for additional milestone payments
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
